Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
This paper introduces an algorithm for the automated diagnosis of referable maculopathy in retinal images for diabetic retinopathy screening. Referable maculopathy is a potentially sight-threatening condition requiring immediate referral to an ophthalmologist from the screening service, and therefore accurate referral is extremely important. The algorithm uses a pipeline of detection and filtering of "peak points" with strong local contrast, segmentation of candidate lesions, extraction of features and classification by a multilayer perceptron. The optic nerve head and fovea are detected, so that the macula region can be identified and scanned. The algorithm is assessed against a reference standard database drawn from the Birmingham City Hospital (UK) diabetic retinopathy screening programme, against two possible modes of use: independent screening, and pre-filtering to reduce human screener workload.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1109/IEMBS.2011.6090914 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Objectives: This study evaluated a novel offline, AI-driven age-related macular degeneration (AMD) screening algorithm against fundus image-only grading and the standard of care (combined Spectral Domain-Optical Coherence Tomography (SD-OCT) and fundus image grading).
Methods: Conducted prospectively at a South Asian tertiary eye hospital, this study utilized a validated smartphone-based non-mydriatic fundus camera to capture macula-centred images. The Medios AI's ability to detect referable AMD was compared to a reference standard image grading, using fundus images from the Zeiss Clarus 700 table-top camera and SD-OCT line scan across fovea.
Cost-effectiveness of fenofibrate versus standard care for reducing the progression of diabetic retinopathy: An economic evaluation based on data from the LENS trial.
Diabet Med
September 2025
Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Aims: The LENS trial demonstrated that fenofibrate slowed the progression of diabetic retinopathy compared to placebo in participants with early diabetic eye disease. We assessed its cost-effectiveness for reducing the progression of diabetic retinopathy versus standard care from a UK National Health Service perspective.
Methods: Resource use and outcome data were collected over follow-up for participants enrolled in LENS.
Objective: To identify diabetic maculopathy features from photographic screening that are predictive of treatment on referral to a tertiary care centre.
Methods: Retrospective review of participants who underwent screening by Singapore Integrated Diabetic Retinopathy Programme from 2015 to 2019. Participants underwent visual acuity (VA) test and non-stereoscopic retinal photographs.
Comment on "A deep learning approach for the screening of referable age-related macular degeneration - Model development and external validation".
J Formos Med Assoc
February 2025
Ophthalmology Department, The First Affiliated Hospital of Inner Mongolia Medical College, 010050, Inner Mongolia, China. Electronic address:
A deep learning approach for the screening of referable age-related macular degeneration - Model development and external validation.
J Formos Med Assoc
December 2024
Department of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan; Department of Ophthalmology, School of Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan; Department of Ophthalmology, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan. Elect
Purpose: To develop a deep learning image assessment software, VeriSee™ AMD, and to validate its accuracy in diagnosing referable age-related macular degeneration (AMD).
Methods: For model development, a total of 6801 judgable 45-degree color fundus images from patients, aged 50 years and over, were collected. These images were assessed for AMD severity by ophthalmologists, according to the Age-Related Eye Disease Studies (AREDS) AMD category.